Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 55 publications
A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide.
Journal: The New England journal of medicine
Published: March 25, 2026
IgG4-Related Disease Presenting With Diffuse Coronary Atherosclerosis Characterized by Marked Lipid-Rich Necrotic Core Burden.
Journal: JACC. Case reports
Published: January 28, 2026
Olpasiran lowering of lipoprotein(a) according to baseline levels: insights from the OCEAN(a)-DOSE study.
Journal: European heart journal
Published: July 16, 2024
DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases.
Journal: Metabolism: clinical and experimental
Published: April 30, 2024
The Off-Treatment Effects of Olpasiran on Lipoprotein(a) Lowering: OCEAN(a)-DOSE Extension Period Results.
Journal: Journal of the American College of Cardiology
Published: April 12, 2024
Hemodynamic Manifestations of Concomitant Radiation-Induced Tricuspid Regurgitation and Pericardial Constriction Undergoing Transcatheter Tricuspid Valve Repair.
Journal: Circulation. Heart failure
Published: September 13, 2023
Evolving Management of Low-Density Lipoprotein Cholesterol: A Personalized Approach to Preventing Atherosclerotic Cardiovascular Disease Across the Risk Continuum.
Journal: Journal of the American Heart Association
Published: June 01, 2023
Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease.
Journal: The New England journal of medicine
Published: November 07, 2022
DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases.
Journal: Journal of diabetes and its complications
Published: November 27, 2021
Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa.
Journal: Journal of thrombosis and haemostasis : JTH
Published: July 02, 2021
Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial.
Journal: The Lancet. Respiratory medicine
Published: March 16, 2021
Last Updated: 09/26/2026